ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Dr. Khera highlights TRAVERSE trial of testosterone replacement therapy
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 269910" data-attributes="member: 13851"><p>[URL unfurl="true"]https://www.excelmale.com/forum/threads/new-and-emergent-preparations-for-male-hypogonadism-treatment.28862/#post-269753[/URL]</p><p></p><p><strong>TRAVERSE/CVD</strong></p><p></p><p><em><strong>*However, it should be recognized that the long-term CV safety of TRT still represents a conflicting issue. One of the most recent meta-analyses showed that TRT does not increase short-term or medium-term CV risk in men with hypogonadism [69]. The same study emphasized the paucity of data evaluating TRT-related long-term CV safety. <u>In addition, although the TRAVERSE study did not report any differences in MACE risk after 2 years of treatment, a mild, although significant, increased risk of arrhythmias, and atrial fibrillation, in particular, as well as of venous thromboembolism, has been reported in the active arm when compared to placebo [23]</u>. <u>The high (>60%) dropout observed during the study and the lack of formal adjudication of the latter events, which were secondary endpoints (venous thromboembolism) and investigator-reported (arrhythmias), represent crucial bias in the data interpretation [23]</u>.</strong></em></p></blockquote><p></p>
[QUOTE="madman, post: 269910, member: 13851"] [URL unfurl="true"]https://www.excelmale.com/forum/threads/new-and-emergent-preparations-for-male-hypogonadism-treatment.28862/#post-269753[/URL] [B]TRAVERSE/CVD[/B] [I][B]*However, it should be recognized that the long-term CV safety of TRT still represents a conflicting issue. One of the most recent meta-analyses showed that TRT does not increase short-term or medium-term CV risk in men with hypogonadism [69]. The same study emphasized the paucity of data evaluating TRT-related long-term CV safety. [U]In addition, although the TRAVERSE study did not report any differences in MACE risk after 2 years of treatment, a mild, although significant, increased risk of arrhythmias, and atrial fibrillation, in particular, as well as of venous thromboembolism, has been reported in the active arm when compared to placebo [23][/U]. [U]The high (>60%) dropout observed during the study and the lack of formal adjudication of the latter events, which were secondary endpoints (venous thromboembolism) and investigator-reported (arrhythmias), represent crucial bias in the data interpretation [23][/U].[/B][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Dr. Khera highlights TRAVERSE trial of testosterone replacement therapy
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top